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Evidence synthesis, and vulnerabilities 
in the translation of evidence into 
recommendations
Five recent reviews of ivermectin in the management of COVID-
19 have achieved widespread social media and public prominence. 
Two were published in the American Journal of Therapeutics[1,2] 
and two are preprints in journals in the Oxford University Press 
stable. [3,4] The fifth is a recently released Cochrane review.[5] In 
three of the five reviews, the summary reports mortality benefits 
using very positive language despite low-quality evidence rendering 
such a conclusion highly uncertain. For example, Kory et al.[1] 
state: ‘Meta-analyses based on 18 randomized controlled treatment 
trials of ivermectin in COVID-19 have found large, statistically 
significant reductions in mortality, time to clinical recovery, and 
time to viral clearance.’
Many readers may have neither the time nor the inclination 
to read the body of the reviews in sufficient detail to pick up the 
extreme frailty of such conclusions, and instead some have further 
disseminated these ‘news-bite’ affirmations of efficacy. Editors and 
reviewers have a responsibility to consider the implications of how 
information is presented, in this case to avoid global overuse of a 
medicine of undetermined efficacy. In some settings, patients have 
resorted to illegally imported or veterinary products when registered 
oral solid dosage forms were unavailable.
This open-access article is distributed under 
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Some clinicians prescribe ivermectin for COVID-19 despite lack of support from any credible South African professional body. They 
argue that when faced by clinical urgency, weak signals of efficacy should trigger action if harm is unlikely. Several recent reviews found 
an apparent mortality benefit by including studies at high risk of bias and with active rather than placebo controls. If these studies are 
discounted, the pooled mortality effect is no longer statistically significant, and evidence of benefit is very weak. Relying on this evidence 
could cause clinical harm if used to justify vaccine hesitancy. Clinicians remain responsible for ensuring that guidance they follow is both 
legitimate and reliable. In the ivermectin debate, evidence-based medicine (EBM) principles have largely been ignored under the guise that 
in a pandemic the ‘rules are different’, probably to the detriment of vulnerable patients and certainly to the detriment of the profession’s 
image. Medical schools and professional interest groups are responsible for transforming EBM from a taught but seldom-used tool into a 
process of lifelong learning, promoting a consistent call for evidence-based and unconflicted debate integral to clinical practice.
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The importance of meticulous 
evidence-based medicine during the 
SARS-CoV-2 pandemic
The premise that authors generate unbiased systematic reviews and 
journals conduct peer review of adequate quality is foundational 
to the scientific medical enterprise, and evidence-based medicine 
(EBM) has taken this as a core principle. By moving away from 
opinion (eminence)-guided practice, EBM has advanced quality 
of care, but struggles to find a voice when weak positive evidence 
is being promoted and the alternative view is simply ‘wait and see’. 
When opinion leaders use electronic media and medical journals to 
express a position ‘backed by evidence’, protestations of uncertainty 
may be overwhelmed by perceived authority and urgency.
In the past few decades, reaching conclusions about the efficacy 
and safety of medical interventions has moved from reliance on 
expert opinion to a more public and formalised collaborative process 
of searching for evidence, appraising its quality, and synthesising 
the data to inform decision-making. The conclusions reached are 
critically dependent on unbiased adherence to all steps, and on the 
quality of the underlying evidence. A critical final process entails 
transforming conclusions about strength and direction of evidence 
into clinically useful recommendations, often by groups independent 
of the review process. A key principle is that decisions can and 
should be made using the best available evidence, even when this is 
imperfect. Relying on anecdotal and weak observational evidence 
can be dangerously misleading, particularly in situations of limited 
biological plausibility.
Considerable time and effort are needed to perform a systematic 
review, and when done well, these are valuable resources for clinical 
and policy decision-making. Systematic reviews, like any human 
endeavour, have vulnerabilities. The more obvious of these can 
be detected using quality appraisal tools, but there are other more 
subtle ways in which bias can occur, rendering results less reliable. 
The rigour of the Cochrane process, and formal collaborative use of 
software such as RevMan,[6] are specifically designed to address many 
of these issues. Registration of systematic review protocols, such as on 
the International Prospective Register of Systematic Reviews (https://
www.crd.york.ac.uk/prospero/), PROSPERO, also aims to minimise 
bias while avoiding duplication of effort.
Examples of bias include undeclared intellectual conflicts of 
interest (where reviewers may not approach a research question 
entirely objectively), inconsistent rigour in ‘risk of bias’ assessment 
(where studies supporting a particular position may be assessed 
differently), inclusion of studies of low reliability, and issues with 
actual meta-analytical methods. The last is particularly problematic 
in an era where software allows almost instantaneous iterative data 
analysis so that it can be difficult to tell whether a submitted data 
analysis plan is truly based on a priori scientific considerations or post 
hoc adoption of a model found to yield preferred results. Other issues 
in meta-analytical technique, such as the handling of double-zero 
studies, weighting methodologies, and the handling of heterogeneity 
and potential small-study effects, engender vigorous debate, as in 
many other developing areas of statistics.
The drive to produce a plausible forest plot may lead to inclusion of 
studies at high risk of bias. Pooling weak evidence will still generate 
an effect estimate. When individual studies contribute very small 
numbers of events, sensitivity analyses omitting several studies at a 
time may leave the overall effect estimator unchanged, but this does 
not mean that the result is robust.
The Bryant et al.[2] review raises several concerns. The authors 
themselves acknowledge that information for all outcomes except 
mortality was weak or very weak. For mild COVID-19, information 
on mortality was available in 5 of 11 trials, with a total of 13 deaths, 
and for severe COVID-19, in 5 trials, with a total of 539 patients, 
200 of which were contributed by the recently withdrawn study by 
Elgazzar et al.[7] The total number of patients in the ivermectin arm 
of the López-Medina et al.[8] study is given as 275 in the forest plots 
and was reported as 200 in the published article, reflecting a decision 
to use ‘as treated’ numbers rather than those in the primary analysis. 
It is these study-level decisions, as well as the decisions about which 
studies to include, that lead to differences in reported review results.
Inclusion of the results of preprint 
studies in meta-analyses circumvents 
peer review
Peer review of articles prior to publication is a valuable tool for 
detection of error, ranging from simple mistakes in calculation and 
reporting to more substantive flaws in design and implementation. 
In extreme cases, peer review may detect fraud. Preprint servers have 
provided rapid access to new research in the current pandemic, but 
this accelerated access comes at the cost of reduced certainty about 
article quality. Published reviews using preprint reports bypass the 
peer review process and may lend undeserved legitimacy to these 
reports, as well as creating a critical weakness in the review itself.
The frailty of the conclusion of ivermectin efficacy has been 
further eroded by the recent withdrawal of the study by Elgazzar et 
al.,[7] which was not considered by Bryant et al.[2] to be at high risk of 
bias. (Bryant et al. went so far as to state that use of preprint server 
studies did not constitute a risk of bias because they peer reviewed 
the studies themselves.) If the authors’ own meta-analysis is repeated, 
first without the studies classified by the authors themselves as at 
high risk of bias, then also excluding the Elgazzar study and others 
with active controls (comparison with another medicine rather than 
a placebo), the pooled effect drifts back towards null (Fig. 1): there is 
no mortality benefit in either mild or severe disease subgroups, and 
no mortality benefit overall (relative risk (RR) 0.41; 95% confidence 
interval (CI) 0.13 - 1.22). This is a finding similar to that reached 
by Roman et al.[4] and reassuring in that the Elgazzar study was also 
correctly identified and omitted. The wisdom of even performing a 
meta-analysis with only six studies and so few events is also moot – 
most events (61%) occurred in the trial labelled as Fonesca et al. in 
the review (but now published by Galan et al.[9]), with no mortality 
benefit (RR 1.06; 95% CI 0.58 - 1.94).
The review by Hill et al.[3] placed the study by Niaee et al.,[10] which 
enrolled patients with varying disease severity, in their mild COVID-
19 group, generating a group of ‘mild to moderate’ disease. This 
analysis leaves the effect size significant for this group after removing 
the study by Elgazzar et al.,[7] but based on a very small numbers of 
events; overall, the mortality benefit is not statistically significant. 
The Niaee study, which has been available in preprint form for more 
than 6 months and has not yet been published in a peer-reviewed 
publication, is itself concerning in that the table presenting participant 
characteristics contains potential errors. One example is that diastolic 
blood pressure is given as a median with an interquartile range, and 
overall this is given as 80 (80 - 80), which, if correct, would mean that 
half the patients had a diastolic blood pressure of exactly 80 mmHg. 
In total, 29% of patients in the study by Niaee et al.[10] were SARS-
CoV-2 polymerase chain reaction-negative (47% overall in the two 
control groups and 20% overall in the four ivermectin groups). It 
is assumed that these patients’ entry into the study was based on 
positive findings on a chest computed tomography scan. It is this sort 
of detail that conscientious and competent peer review is designed to 
address. If a conservative approach is taken and the study by Niaee et 
al.[10] is also excluded from the pooled analysis while these concerns 
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are addressed, the potential overall mortality RR is a non-significant 
0.67 (95% CI 0.25 - 1.79), drifting even closer to null. This movement 
of the estimate of treatment effect towards the null is an expected and 
frequent phenomenon as small weak studies are re-interrogated, and 
studies with a higher publication hurdle (because of negative results) 
are finally released.
The recently released high-quality Cochrane review[5] reaches 
similar conclusions: only 4 studies (2 for mild and 2 for moderate/
severe disease) were considered appropriate for inclusion in the 
pooled mortality analyses, and no convincing evidence of efficacy 
was found. The meticulous attention to detail in this well-conducted 
review demonstrates the enormous effort required to perform a 
systematic review well. It can be argued that strict inclusion criteria, 
such as limiting the review to randomised controlled trials, have left 
out a large body of evidence. However, the aim is to prevent making 
mistakes by excluding unreliable information: as the proportion 
of unreliable information rises, so does the chance of reaching 
a mistaken conclusion. There is a place for observational data, 
particularly in the assessment of safety, but reliable estimates of 
efficacy must be based on reliable data. The emotional appeal of ‘real-
world evidence’, and the demands of a pandemic, should not result 
in over-reliance on questionable or potentially biased data. Patients’ 
lives rely on the rigour of the entire process, from clinical trial design 
and execution to the development of clinical practice guidelines.
Fig. 1 demonstrates the effect of changing trial inclusion criteria. 
A  liberal policy of inclusion yields a larger effect size, and also 
generates a ‘significant’ benefit; as the high-risk studies, and the 
studies using an active comparator, are progressively excluded, the 
effect drifts back towards null; and the inclusion of a large negative 
study such as that by Vallejos et al.[11] pushes this into a clearer lack of 
any signal of benefit, although the evidence is still incomplete.
Prescribing pressures and harm as 
opportunity cost
The ivermectin argument that ‘even if not clearly efficacious, it can’t 
do any harm’ has opportunity costs: individuals may feel safer taking 
ivermectin, and indulge in more risky behaviour, its promotion on 
some social media sites places it as an alternative to vaccination, and 
its inclusion in therapeutic cocktails lends credibility to other useless 
or potentially harmful components. Users, convinced of unproven 
benefits, may be reluctant to enrol in appropriate, randomised, 
placebo-controlled trials.
Another clear harm of this approach is that it legitimises a laissez-
faire approach to clinical care, where instead of prescribers relying 
on regulatory authorities and conscientious evidence-based practice, 
it is seen as reasonable to prescribe based on opinions expressed on 
social media platforms.
Clinical influences of group think and 
social media facilitation
The psychological process of group think[12] further exacerbates 
this. The need for consensus leads to ignoring divergent opinions 
and explanations; this process is self-perpetuating in that the more 
strongly a group embraces a position, the more invested it becomes 
in demonstrating its validity, leading to ‘cherry-picking’ of supporting 
evidence. This selected evidence further strengthens beliefs, to the 
extent that countervailing explanations are stridently opposed, often 
accompanied by ad hominem attacks on those attempting to voice 
contrary views.
Social media facilitates group think, not only by allowing rapid 
dissemination of ever more extreme positions, but also by vastly 
increasing membership through international recruitment. In larger 
groups there will be higher absolute numbers at the extremes, leading 
to further polarisation.[13]
Societal expectations for medical 
professionalism, and the clinician as 
scientist
Society entrusts clinicians to provide healthcare guidance. The 
implicit assumption is that the individual clinician-scientist will 
have carefully researched an issue and reached a reasoned and safe 
decision, which is then conveyed to a patient. When evidence is weak, 
All studies from Bryant et al.[2]
Subtotal (I2=49.4%; p=0.031)
Removing studies at high risk of bias
Subtotal (I2=61.5%; p=0.011)
Also removing studies with an active comparator
Subtotal (I2=55.7%; p=0.046)
Also removing the study by Niaee et al.[10]
Subtotal (I2=18.7%; p=0.296)
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Fig. 1. Ivermectin: Impact of study selection on overall mortality effect in COVID-19 (all severities). I2 measures the degree of inconsistency across studies, with 
higher values indicating greater heterogeneity. (RR = relative risk; CI = confidence interval.)
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complex and value laden, this is technically difficult, and reliance 
on unbiased guidance carefully synthesised by experts is entirely 
appropriate. It is precisely in times of uncertainty and perceived 
haste that regulatory authorities and careful reviews are most useful 
in preventing therapeutic mayhem. In South Africa, no credible 
professional body has yet supported the use of ivermectin, and the 
promoters of its use are doing so in the general press, on websites and 
through social media. It is arguably unethical, medicolegally fraught, 
and unprofessional to adopt a position so far removed from that 
entrusted to us by society.
Clinicians remain responsible for ensuring that guidance they 
follow is both legitimate and reliable. In the ivermectin debate, EBM 
principles have largely been ignored under the guise that during 
a pandemic the ‘rules are different’, probably to the detriment of 
vulnerable patients and certainly to the detriment of the profession’s 
image. Medical schools and professional interest groups are 
responsible for transforming EBM from a taught but seldom used 
tool into a process of lifelong learning, promoting a consistent call for 
evidence-based and unconflicted debate integral to clinical practice.
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